We searched PubMed and Cochrane Library from Jan 1, 2000, to April 30, 2020, with the search terms “pre-eclampsia” and “hypertensive disorders in pregnancy”. We cross-referenced these terms with: “pathophysiology”, “definition”, “guidelines”, “prediction”, “prevention”, “management”, “clinical trials”, “aspirin”, and “calcium”. We also searched for guidelines from international societies and clinical specialty colleges and limited our search to publications in English. We focused on
SeminarPre-eclampsia
Introduction
Pre-eclampsia complicates about 3–5% of all pregnancies and is estimated to cause at least 42 000 maternal deaths annually.1, 2, 3 For every loss related to pre-eclampsia, at least 50–100 women have substantial morbidity.2, 4, 5 Low-income and middle-income countries (LMIC) have the highest burden of major complications because of scarce resources and poorer access to adequate obstetric care and family planning services than high-income countries.6, 7
Pre-eclampsia can present in many ways; it can be diagnosed after a woman presents with a seizure, breathlessness, severe epigastric pain, and massive placental abruption, or diagnosed at a routine antenatal consultation if a woman is asymptomatic but hypertensive.
Although keenly sought, no treatment has been found that affects disease progression. Current approaches to improving clinical outcomes in pre-eclampsia centre on prevention, prompt diagnosis, and stratification of care. If a woman diagnosed with pre-eclampsia is at an early gestation, the mainstay is expectant management with timing of birth planned to optimise maternal and fetal outcomes.
New trials and cohort studies have given insights into the prevention of pre-eclampsia, diagnostic and prognostic tools, and the optimal gestation to plan birth. This Seminar provides an update on the clinical management of pre-eclampsia. It focuses on evidence generated in the past 5 years and puts current findings into context as to how they could be used to improve clinical care and pregnancy outcomes.
Section snippets
Diagnosis and clinical definition
Pre-eclampsia is a progressive disease of pregnancy involving multiple organ systems. The clinical definition has evolved over time, from simply hypertension and proteinuria, to a broader classification that recognises the complex multi-organ system involvement caused by the disease. International guidelines agree that pre-eclampsia can be defined as new onset hypertension (systolic blood pressure sustained at ≥140 mm Hg or diastolic blood pressure sustained at ≥90 mm Hg, or both) with
Risk factors
Clinical risk factors for pre-eclampsia are summarised in table 1,21, 22 with the highest risk factors being history of pre-eclampsia (an 8-times increase in risk, although the risk might be lower for those with pre-eclampsia in a first pregnancy but not in subsequent pregnancy) and chronic hypertension (a 5-times increase in risk). A history of preterm pre-eclampsia carries the greatest risk of developing pre-eclampsia with around 25–30% of women experiencing recurrent disease.23, 24, 25, 26,
Pathogenesis of pre-eclampsia
In normal early pregnancy, the placenta remodels local uterine vasculature, setting up optimal conditions for nutrient and oxygen exchange throughout pregnancy. Extravillous placental trophoblast cells migrate through the inner third of the myometrium of the uterus and remove the smooth muscle from the maternal spiral arterioles,28 rendering the ends of the vessels unable to constrict. Consequently, the terminal part of the spiral arterioles remains wide open and the net result is a high
Predictive and diagnostic tools for pre-eclampsia
The two active strategies being pursued to decrease short-term and long-term adverse outcomes caused by pre-eclampsia are predicting who is at high risk of developing the disease (screening for pre-eclampsia), and using tests as diagnostic adjuncts to exclude the likelihood that a woman has pre-eclampsia.
Aspirin
Aspirin is the only preventive drug treatment for pre-eclampsia that is supported by strong evidence. A 2019 Cochrane review concluded there is high-quality evidence that low-dose aspirin taken daily from the end of the first trimester until 36 weeks' gestation reduces the risk of developing pre-eclampsia by around 18% (relative risk 0·82; 95% CI 0·77–0·82).64 The risk reduction for preterm pre-eclampsia is likely to be greater than for pre-eclampsia in general.65, 66
How aspirin prevents
Management of women with pre-eclampsia
Once diagnosed, pre-eclampsia is often a progressive condition and maternal organ function deteriorates with time. No drug has been discovered that clearly slows disease progression and the only option to stop the disease is to deliver the fetus and placenta. Therefore, the overall approach to management is to deliver the baby and placenta at term gestation, or, if preterm pre-eclampsia is diagnosed, to try expectant management of the pregnancy until a more advanced gestation is reached (figure
Long-term complications of pre-eclampsia
Large cohort studies and meta-analyses have established that pre-eclampsia confers an increased risk of major chronic diseases in later life including many cardiovascular complications.106, 107, 108, 109, 110 A 2017 systematic review including more than 6·4 million women showed that those with a history of pre-eclampsia have a 4-times greater risk of heart failure, a 2·5-times greater risk of coronary heart disease, a 1·8-times greater risk of stroke, and an overall 2·2-times greater risk of
Conclusion and future directions
The 2019 Maternal Mortality update from the WHO report125 illuminated the major contribution of pre-eclampsia and eclampsia to worldwide maternal deaths. There is much to be done to decrease the morbidity and mortality caused by this disease.
Most of the maternal deaths arising from pre-eclampsia occur in LMICs. There needs to be implementation research to determine how best to allocate scarce resources to save the greatest number of lives. Options might include improving access to antenatal
Search strategy and selection criteria
References (134)
- et al.
Global and regional estimates of preeclampsia and eclampsia: a systematic review
Eur J Obstet Gynecol Reprod Biol
(2013) - et al.
Global causes of maternal death: a WHO systematic analysis
Lancet Glob Health
(2014) - et al.
The hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice
Hypertension
(2018) - et al.
Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary
J Obstet Gynaecol Can
(2014) - et al.
Preeclampsia recurrence and prevention
Semin Perinatol
(2007) - et al.
Severe, very early onset preeclampsia: subsequent pregnancies and future parental cardiovascular health
Eur J Obstet Gynecol Reprod Biol
(2008) - et al.
Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia
Am J Obstet Gynecol
(2006) - et al.
Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis
Am J Obstet Gynecol
(1986) - et al.
Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial
Lancet
(2019) - et al.
Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy
Placenta
(2009)
Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia
Placenta
The placental basis of fetal growth restriction
Obstet Gynecol Clin North Am
Decidual vasculopathy in preeclampsia: lesion characteristics relate to disease severity and perinatal outcome
Placenta
Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery
Placenta
Placental histopathological lesions in correlation with neonatal outcome in preeclampsia with and without severe features
Pregnancy Hypertens
Innate immune cells in the placental bed in healthy pregnancy and preeclampsia
Placenta
Pre-eclampsia: more than pregnancy-induced hypertension
Lancet
Role of exosomes in placental homeostasis and pregnancy disorders
Prog Mol Biol Transl Sci
Accuracy of angiogenic biomarkers at ≤20 weeks' gestation in predicting the risk of pre-eclampsia: a WHO multicentre study
Pregnancy Hypertens
Prospective biomarkers in preterm preeclampsia: a review
Pregnancy Hypertens
Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia
Pregnancy Hypertens
Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial
Lancet
Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial
Lancet
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
Lancet
Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis
Am J Obstet Gynecol
Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis
Am J Obstet Gynecol
Preventing preeclampsia with aspirin: does dose or timing matter?
Am J Obstet Gynecol
Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials
Lancet
Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial
Am J Obstet Gynecol
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction
Am J Obstet Gynecol
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol
Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol
Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial
Am J Obstet Gynecol
Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial
Lancet
Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial
Lancet
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model
Lancet
Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis
BMJ
Trends in maternal mortality: 1990 to 2015
Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States
Hypertens Pregnancy
A new look at care in pregnancy: simple, effective interventions for neglected populations
PLoS One
Hypertensive disorders in pregnancy: 2019 national guideline
S Afr Med J
Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222
Obstet Gynecol
Hypertension in pregnancy: diagnosis and management
The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014
Aust N Z J Obstet Gynaecol
Placental pathology in relation to uterine artery Doppler findings in pregnancies with severe intrauterine growth restriction and abnormal umbilical artery Doppler changes
Am J Perinatol
Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research
Circulation
European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults
Blood Press Monit
Can we use the Omron T9P automated blood pressure monitor in pregnancy?
Hypertens Pregnancy
Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review
BMJ
Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis
BMJ
Cited by (364)
Ambient air pollution and hypertensive disorders of pregnancy in Rome
2024, Environmental ResearchModel construction and application for predicting pre-eclampsia by Sonoclot coagulation analyzer
2024, Non-coding RNA ResearchUrinary concentration of Cathepsin D as a relievable marker of preeclampsia
2024, Pregnancy Hypertension